share_log
Moomoo 24/7 ·  04/24 07:59

Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics宣佈首批隊列已完成其評估Ras、Nf1和Raf突變癌症Pas-004的1期試驗的初始給藥

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論